HEDIS® Results
Medicaid HEDIS® Annual Rates.
Molina’s scores for the past year are below. You can see how Molina performs compared to our target goal.
Measure |
2022 |
Goal |
Adherence to Antipsychotic Medications for Individuals with Schizophrenia (SAA) |
40.91% |
64.52% |
Annual Dental Visits (ADV) |
45.47% |
53.67% |
Antidepressant Medication Management (AMM) Effective Continuation Phase Treatment |
43.94% |
46.09% |
Appropriate Testing for Pharyngitis (CWP) |
64.36% |
74.02% |
Appropriate Treatment for Upper Respiratory Infection (URI) |
90.70% |
92.46% |
Asthma Medication Ratio (AMR) Total |
53.90% |
68.21% |
Avoidance of Antibiotic Treatment for Acute Bronchitis / Bronchiolitis (AAB) |
67.36% |
58.74% |
Breast Cancer Screening (BCS) |
39.60% |
53.96% |
Cervical Cancer Screening (CCS) |
37.96% |
60.83% |
Childhood Immunization Status (CIS) Combination #10 |
25.06% |
39.42% |
Chlamydia Screening in Women (CHL) Total |
54.88% |
60.24% |
Comprehensive Diabetes Care (CDC) BP Control < 140/90 |
NQ |
65.21% |
Comprehensive Diabetes Care (CDC) HbA1c Control <8.0% |
NQ |
52.80% |
Comprehensive Diabetes Care (CDC) Eye Exam |
NQ |
54.74% |
Controlling High Blood Pressure (CBP) |
54.74% |
63.50% |
Diabetes Screening for People with Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medications (SSD) |
73.26% |
81.21% |
Follow-Up After Emergency Department Visit for Alcohol and Other Drug Abuse or Dependence (FUA) 7-Day Follow-Up Total |
11.91% |
16.16% |
Follow-Up After Emergency Department Visit for Mental Illness (FUM) 7-Day Follow-Up Total |
52.25% |
45.35% |
Follow-Up After Hospitalization for Mental Illness (FUH) 7-Day Follow-Up Total |
33.17% |
42.75% |
Follow-Up After High-Intensity Care for Substance Use Disorder (FUI) 7-Day Follow-Up Total |
36.71% |
37.86% |
Follow-Up for Children Prescribed ADHD Medication (ADD) Continuation and Maintenance Phase |
NA |
55.40% |
Immunizations for Adolescents (IMA) Combination #2 |
30.66% |
39.16% |
Initiation and Engagement of Alcohol and Other Drug Dependence Treatment (IET) Engagement of AOD Treatment Total |
19.98% |
16.57% |
Metabolic Monitoring for Children and Adolescents on Antipsychotics (APM) Total |
37.80% |
39.29% |
Pharmacotherapy for Opioid Use Disorder (POD) Total |
12.53% |
33.15% |
Pharmacotherapy Management of COPD Exacerbation (PCE) Systemic Corticosteroids |
54.39% |
74.76% |
Pharmacotherapy Management of COPD Exacerbation (PCE) Bronchodilator |
70.18% |
87.83% |
Plan All-Cause Readmissions (PCR) Observed-to-Expected Ratio 18-64 Years |
85.68% |
≤ 94.44% |
Prenatal and Postpartum Care (PPC) Timeliness of Prenatal Care |
75.43% |
87.83% |
Prenatal and Postpartum Care (PPC) Postpartum Care |
66.18% |
80.00% |
Prenatal Immunization Status (PRS) Combination Rate |
16.26% |
27.32% |
Risk of Continued Opioid Use (COU) 31-Day Total |
2.24% |
≤ 2.35% |
Statin Therapy for Patients with Cardiovascular Disease (SPC) Received Statin Therapy Total |
77.57% |
82.29% |
Statin Therapy for Patients with Cardiovascular Disease (SPC) Statin Adherence 80% Total |
67.47% |
73.75% |
Statin Therapy for Patients with Diabetes (SPD) Received Statin Therapy |
58.29% |
68.32% |
Statin Therapy for Patients with Diabetes (SPD) Statin Adherence 80% |
64.03% |
70.00% |
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (APP) Total |
68.85% |
65.63% |
Use of Imaging Studies for Low Back Pain (LBP) |
78.26% |
76.82% |
Use of Opioids at High Dosage (HDO) |
5.47% |
≤ 2.65% |
Use of Opioids from Multiple Providers (UOP) Multiple Prescribers and Multiple Pharmacies |
6.90% |
≤ 0.90% |
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (WCC) BMI Percentile |
71.05% |
82.73% |
NA = Not Available Due to Small Denominator
NB = No Benefit
NR = Not Reported
NQ = Not Required
BR = Biased Rate